SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 300 | Europe, Japan, US, RoW | Pembrolizumab, Dostarlimab, Belrestotug, EOS884448, GSK4428859A, GSK6097608 | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 01/25 | 01/28 | | |
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments |
|
|
| Recruiting | N/A | 2000 | Europe, US, RoW | Plasma sample collection | OncoHost Ltd. | Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma | 10/29 | 10/29 | | |
